The FDA has granted approval to Aurobindo Pharma Limited for their generic version of adapalene and benzoyl peroxide, intensifying competition in the topical acne market. This latest authorization is expected to provide cost-effective alternatives while potentially pressuring the market share of branded prescription therapies.